Drugs

, Volume 71, Issue 17, pp 2327–2345

Eculizumab

A Review of its Use in Paroxysmal Nocturnal Haemoglobinuria
Adis Drug Evaluation

Abstract

Eculizumab is a humanized monoclonal antibody indicated for the treatment of paroxysmal nocturnal haemoglobinuria (PNH). It binds specifically and with high affinity to the complement protein C5, thereby preventing the formation of the terminal complement complex C5b-9, which mediates cell lysis. In patients with PNH, eculizumab inhibits terminal complement mediated intravascular haemolysis.

In clinical trials of PNH patients, eculizumab reduced intravascular haemolysis compared with baseline and placebo, as determined by significantly decreased lactate dehydrogenase (LDH) levels. Significant reductions in LDH levels were achieved within the first week of treatment, with near normal levels achieved at week 2 and maintained throughout longer term treatment, including periods of up to 36 months. Eculizumab achieved rapid and sustained efficacy, regardless of baseline LDH levels or platelet counts.

In adults with PNH, eculizumab treatment for 26 weeks achieved stabilization of haemoglobin levels in significantly more patients than placebo treatment, and reduced the requirement for packed red cell transfusions to a significantly greater extent than placebo. Half of all patients in the eculizumab group became transfusion independent compared with no patients in the placebo group. Eculizumab was also associated with significant improvements in fatigue and health-related quality-of-life scores in several trials. Over the long term, the survival of PNH patients treated with eculizumab was normalized.

Eculizumab was generally well tolerated in clinical trials of PNH patients, including treatment periods of up to 5.5 years. The risk of Neisseria meningitidis is increased with eculizumab and patients must be vaccinated prior to treatment and monitored throughout.

Thus, eculizumab, the first targeted terminal complement inhibitor, provides an effective and generally well tolerated treatment for PNH patients, who have previously been without adequate treatment options.

References

  1. 1.
    Parker CJ. The pathophysiology of paroxysmal nocturnal hemoglobinuria. Exp Hematol 2007 Apr; 35(4): 523–33PubMedCrossRefGoogle Scholar
  2. 2.
    Kelly R, Richards S, Hillmen P, et al. The pathophysiology of paroxysmal nocturnal hemoglobinuria and treatment with eculizumab. Ther Clin Risk Manag 2009; 5: 911–21PubMedCrossRefGoogle Scholar
  3. 3.
    Parker C. Eculizumab for paroxysmal nocturnal haemoglobinuria. Lancet 2009 Feb 28; 373(9665): 759–67PubMedCrossRefGoogle Scholar
  4. 4.
    Gargiulo L, Lastraiolo S, Cerruti G, et al. Highly homologous T-cell receptor beta sequences support a common target for autoreactive T cells in most patients with paroxysmal nocturnal hemoglobinuria. Blood 2007; 109: 5036–42PubMedCrossRefGoogle Scholar
  5. 5.
    Hillmen P, Muus P, Duhrsen U, et al. Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria. Blood 2007 Dec 1; 110(12): 4123–8PubMedCrossRefGoogle Scholar
  6. 6.
    Incidence of VTE and relative risk in PNH vs inherited hypercoagulable states. Cheshire (CT): Alexion Pharmaceuticals Inc., 2011. (Data on file)Google Scholar
  7. 7.
    De Stefano V, Rossi E, Paciaroni K, et al. Screening for inherited thrombophilia: indications and therapeutic implications. Haematologica 2002; 87: 1095–108PubMedGoogle Scholar
  8. 8.
    Hill A, Richards SJ, Hillmen P. Recent developments in the understanding and management of paroxysmal nocturnal haemoglobinuria. Br J Haematol 2007 May; 137(3): 181–92PubMedCrossRefGoogle Scholar
  9. 9.
    Rother RP, Bell L, Hillmen P, et al. The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin. JAMA 2005 Apr; 292(13): 1653–62CrossRefGoogle Scholar
  10. 10.
    Schäfer A, Wiesmann F, Neubauer S, et al. Rapid regulation of platelet activation in vivo by nitric oxide. Circulation 2004; 109: 1819–22PubMedCrossRefGoogle Scholar
  11. 11.
    Hillmen P, Lewis SM, Bessler M, et al. Natural history of paroxysmal nocturnal hemoglobinuria. N Engl J Med 1995; 333(19): 1253–8PubMedCrossRefGoogle Scholar
  12. 12.
    Soliris (eculizumab). Prescribing information [online]. Available from URL: http://www.soliris.net/ [Accessed 2011 Oct5]
  13. 13.
    Rother RP, Rollins SA, Mojcik CF, et al. Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Nat Biotechnol 2007 Nov; 25(11): 1256–64PubMedCrossRefGoogle Scholar
  14. 14.
    European Medicines Agency. Soliris 300 mg: summary of product characteristics. 2007 [online]. Available from URL: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000791/WC500054208.pdf [Accessed 2011 Sep 18]
  15. 15.
    Helley D, de Latour RP, Porcher R, et al. Evaluation of hemostasis and endothelial function in patients with paroxysmal nocturnal hemoglobinuria receiving eculizumab. Haematologica 2010 Apr; 95(4): 574–81PubMedCrossRefGoogle Scholar
  16. 16.
    Hill A, Rother RP, Wang X, et al. Effect of eculizumab on haemolysis-associated nitric oxide depletion, dyspnoea, and measures of pulmonary hypertension in patients with paroxysmal nocturnal haemoglobinuria. Br J Haematol 2010 May; 149(3): 414–25PubMedCrossRefGoogle Scholar
  17. 17.
    Röth A, Hock C, Konik A, et al. Chronic treatment of paroxysmal nocturnal hemoglobinuria patients with eculizumab: safety, efficacy, and unexpected laboratory phenomena. Int J Hematol 2011 Jun; 93(6): 704–14PubMedCrossRefGoogle Scholar
  18. 18.
    Risitano AM, Perna F, Selleri C. Achievements and limitations of complement inhibition by eculizumab in paroxysmal nocturnal hemoglobinuria: the role of complement component 3. Mini Rev Med Chem 2011 Jun; 11(6): 528–35PubMedCrossRefGoogle Scholar
  19. 19.
    Hill A, Rother RP, Arnold L, et al. Eculizumab prevents intravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria and unmasks low-level extravascular hemolysis occurring through C3 opsonization. Haematologica 2010 Apr; 95(4): 567–73PubMedCrossRefGoogle Scholar
  20. 20.
    Hill A, Socie G, Muus P, et al. Terminal complement inhibitor eculizumab improves complement-mediated platelet consumption and thrombocytopenia in patients with paroxysmal nocturnal hemoglobinuria (PNH) [abstract]. Br J Haematol 2010; 149: 10CrossRefGoogle Scholar
  21. 21.
    Kelly RJ, Hill A, Arnold LM, et al. Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival. Blood 2011 Jun 23; 117(25): 6786–92PubMedCrossRefGoogle Scholar
  22. 22.
    Kelly R, Arnold L, Richards S, et al. The management of pregnancy in paroxysmal nocturnal haemoglobinuria on long term eculizumab. Br J Haematol 2010 May; 149(3): 446–50PubMedCrossRefGoogle Scholar
  23. 23.
    Hillmen P, Hall C, Marsh JC, et al. Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria. N Engl J Med 2004 Feb 5; 350(6): 552–9PubMedCrossRefGoogle Scholar
  24. 24.
    Hill A, Hillmen P, Richards SJ, et al. Sustained response and long-term safety of eculizumab in paroxysmal nocturnal hemoglobinuria. Blood 2005 Oct 1; 106(7): 2559–65PubMedCrossRefGoogle Scholar
  25. 25.
    Hillmen P, Young NS, Schubert J, et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med 2006 Sep 21; 355(12): 1233–43PubMedCrossRefGoogle Scholar
  26. 26.
    Brodsky RA, Young NS, Antonioli E, et al. Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Blood 2008 Feb 15; 111(4): 1840–7PubMedCrossRefGoogle Scholar
  27. 27.
    Kanakura Y, Ohyashiki K, Shichishima T, et al. Safety and efficacy of the terminal complement inhibitor eculizumab in Japanese patients with paroxysmal nocturnal hemoglobinuria: the AEGIS clinical trial. Int J Hematol 2011 Jan; 93(1): 36–46PubMedCrossRefGoogle Scholar
  28. 28.
    Kim JS, Lee JW, Kim BK, et al. The use of the complement inhibitor eculizumab (Soliris®) for treating Korean patients with paroxysmal nocturnal hemoglobinuria. Korean J Hematol 2010 Dec; 45(4): 269–74PubMedCrossRefGoogle Scholar
  29. 29.
    Schubert J, Hillmen P, Röth A, et al. Eculizumab, a terminal complement inhibitor, improves anaemia in patients with paroxysmal nocturnal haemoglobinuria. Br J Haematol 2008 Jun; 142(2): 263–72PubMedCrossRefGoogle Scholar
  30. 30.
    Hillmen P, Elebute M, Kelly R, et al. Long-term effect of the complement inhibitor eculizumab on kidney function in patients with paroxysmal nocturnal hemoglobinuria. Am J Hematol 2010 Aug; 85(8): 553–9PubMedCrossRefGoogle Scholar
  31. 31.
    Brodsky RA, de Castro III C, Schrezenmeier H, et al. Long term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal hemoglobinuria (PNH) [abstract no. 4237 plus poster]. 52nd American Society of Hematology (ASH) Annual Meeting; 2010 Dec 4–7; Orlando (FL)Google Scholar
  32. 32.
    Danilov AV, Smith H, Craigo S, et al. Paroxysmal nocturnal hemoglobinuria (PNH) and pregnancy in the era of eculizumab [letter]. Leuk Res 2009; 33(6): e4–5PubMedCrossRefGoogle Scholar
  33. 33.
    Harrison LH, Trotter CL, Ramsay ME. Global epidemiology of meningococcal disease. Vaccine 2009 Jun; 27 Suppl. 2: B51–63PubMedCrossRefGoogle Scholar
  34. 34.
    Bouts A, Monnens L, Davin J-C, et al. Insufficient protection by Neisseria meningitidis vaccination alone during eculizumab therapy [letter]. Pediatr Nephrol 2011; 26: 1919–20PubMedCrossRefGoogle Scholar
  35. 35.
    Parker C, Omine M, Richards S, et al. Diagnosis and management of paroxysmal nocturnal hemoglobinuria. Blood 2005 Jul; 106(12): 3699–709PubMedCrossRefGoogle Scholar
  36. 36.
    Saso R, Marsh J, Cevreska L, et al. Bone marrow transplants for paroxysmal nocturnal haemoglobinuria. Br J Haematol 1999; 104: 392–6PubMedCrossRefGoogle Scholar
  37. 37.
    Clark D, Butler SA, Braren V, et al. The kidneys in paroxysmal nocturnal hemoglobinuria. Blood 1981; 57: 83–9PubMedGoogle Scholar
  38. 38.
    Rimola J, Martin J, Puig J, et al. The kidney in paroxysmal nocturnal hemoglobinuria: MRI findings. Br J Radiol 2004; 77: 953–6PubMedCrossRefGoogle Scholar
  39. 39.
    Brodsky RA. How I treat paroxysmal nocturnal hemoglobinuria. Blood 2009 Jun 25; 113(26): 6522–7PubMedCrossRefGoogle Scholar
  40. 40.
    Kim JS, Lee JW, Yoon S-S, et al. Association between elevated hemolysis at diagnosis and early mortality and risk of thrombosis in paroxysmal nocturnal hemglobinuria (PNH) patients with cytopenia [abstract no. 4241]. 52nd American Society of Hematology (ASH) Annual Meeting; 2010 Dec 4–7; Orlando (FL)Google Scholar
  41. 41.
    Lee JW, Jang JH, Lee JH, et al. High prevalence and mortality associated with thromboembolism in Asian patients with paroxysmal nocturnal hemoglobinuria (PNH) [abstract no. 0505]. Haematologica 2010; 95 Suppl. 2: 205Google Scholar
  42. 42.
    van Bijnen ST, Vermeer H, Mourisse JM, et al. Cardiopulmonary bypass in a patient with classic paroxysmal nocturnal hemoglobinuria during treatment with eculizumab [letter]. Eur J Haematol 2011; 87(4): 376–8PubMedCrossRefGoogle Scholar
  43. 43.
    Schutgens RE, Pruissen-Peeters KA, Muus P. A cascade of thromboembolic processes in a patient with paroxysmal nocturnal haemoglobinuria terminated by treatment with eculizumab [letter]. Thromb Haemost 2011 Aug; 106(2): 283–5CrossRefGoogle Scholar
  44. 44.
    Wiedermann CJ, Stockner I. Warfarin-induced bleeding complications: clinical presentation and therapeutic options. Thromb Res 2008; 122 Suppl. 2: S13–18PubMedCrossRefGoogle Scholar
  45. 45.
    Emadi A, Brodsky RA. Successful discontinuation of anticoagulation following eculizumab administration in paroxysmal nocturnal hemoglobinuria [letter]. Am J Hematol 2009 Oct; 84(10): 699–701PubMedCrossRefGoogle Scholar
  46. 46.
    Luzzatto L, Risitano AM, Notaro R. Paroxysmal nocturnal hemoglobinuria and eculizumab. Haematologica 2010 Apr; 95(4): 523–6PubMedCrossRefGoogle Scholar
  47. 47.
    Nishimura J, Kanakura Y, Ware RE, et al. Clinical course and flow cytometric analysis of paroxysmal nocturnal hemoglobinuria in the United States and Japan. Medicine 2004 May; 83(3): 193–207PubMedCrossRefGoogle Scholar
  48. 48.
    US National Institutes of Health. Eculizumab pharmacokinetics/pharmacodynamics study in pediatric/adolescent PNH subjects [online]. Available from URL: http://clinicaltrials.gov/ct2/show/NCT00867932 [Accessed 2011 Oct 10]
  49. 49.
    Curran KJ, Kernan NA, Prockop SE, et al. Paroxysmal nocturnal hemoglobinuria (PNH) in pediatric patients: review of a single center series [abstract no. 223]. 52nd American Society of Hematology (ASH) Annual Meeting; 2010 Dec 4–7; Orlando (FL)Google Scholar
  50. 50.
    Meningitis in PNH patients treated with eculizumab in clinical trials. Cheshire (CT): Alexion Pharmaceuticals Inc., 2011. (Data on file)Google Scholar
  51. 51.
    US National Institutes of Health. ClinicalTrials.gov [online]. Available from URL: http://clinicaltrials.gov/ct2/results?term=eculizumab [Accessed 2011 Sep 5]
  52. 52.
    Stegall MD, Diwan T, Raghavaiah S, et al. Terminal complement inhibition decreases antibody-mediated rejection in senstitized renal transplant recipients. Am J Transplant. Epub 2011 SepGoogle Scholar

Copyright information

© Adis Data Information BV 2011

Authors and Affiliations

  1. 1.Adis, a Wolters Kluwer BusinessMairangi Bay, North Shore, AucklandNew Zealand

Personalised recommendations